ATE538798T1 - Zusammensetzungen und ihre verwendungen gegen niedermolekulare ptpase - Google Patents
Zusammensetzungen und ihre verwendungen gegen niedermolekulare ptpaseInfo
- Publication number
- ATE538798T1 ATE538798T1 AT06771192T AT06771192T ATE538798T1 AT E538798 T1 ATE538798 T1 AT E538798T1 AT 06771192 T AT06771192 T AT 06771192T AT 06771192 T AT06771192 T AT 06771192T AT E538798 T1 ATE538798 T1 AT E538798T1
- Authority
- AT
- Austria
- Prior art keywords
- ptpase
- compositions
- diabetes
- methods
- low molecular
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 102100040323 Low molecular weight phosphotyrosine protein phosphatase Human genes 0.000 abstract 2
- 101710186835 Low molecular weight phosphotyrosine protein phosphatase Proteins 0.000 abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 230000000692 anti-sense effect Effects 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 208000006575 hypertriglyceridemia Diseases 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000010200 validation analysis Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
- C12Y301/03048—Protein-tyrosine-phosphatase (3.1.3.48)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Means For Warming Up And Starting Carburetors (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68440005P | 2005-05-24 | 2005-05-24 | |
| US74220705P | 2005-12-01 | 2005-12-01 | |
| PCT/US2006/020272 WO2006127913A2 (en) | 2005-05-24 | 2006-05-24 | Modulation of lmw-ptpase expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE538798T1 true ATE538798T1 (de) | 2012-01-15 |
Family
ID=37452845
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06771192T ATE538798T1 (de) | 2005-05-24 | 2006-05-24 | Zusammensetzungen und ihre verwendungen gegen niedermolekulare ptpase |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20090221671A1 (https=) |
| EP (2) | EP2462937A1 (https=) |
| JP (1) | JP2008541729A (https=) |
| AT (1) | ATE538798T1 (https=) |
| AU (1) | AU2006249925A1 (https=) |
| CA (1) | CA2609180A1 (https=) |
| WO (1) | WO2006127913A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8951981B2 (en) * | 2009-06-16 | 2015-02-10 | Curna, Inc. | Treatment of paraoxonase 1 (PON1) related diseases by inhibition of natural antisense transcript to PON1 |
| RU2619185C2 (ru) * | 2009-12-23 | 2017-05-12 | Курна, Инк. | Лечение заболеваний, связанных с разобщающим белком 2 (ucp2), путем ингибирования природного антисмыслового транскрипта к ucp2 |
| KR101853509B1 (ko) * | 2010-01-06 | 2018-04-30 | 큐알엔에이, 인크. | 췌장 발달 유전자에 대한 천연 안티센스 전사체의 억제에 의한 췌장 발달 유전자와 관련된 질환의 치료 |
| TWI524160B (zh) | 2013-04-16 | 2016-03-01 | 瓦特洛威電子製造公司 | 具有整合光學感測功能之程序控制器 |
| MX2018015722A (es) | 2016-07-01 | 2019-05-27 | Hoffmann La Roche | Oligonucleotidos antisentido para modular expresion del requisito de alta temperatura a 1 (htra1). |
| US20190055564A1 (en) * | 2017-06-01 | 2019-02-21 | F. Hoffmann-La Roche Ag | Antisense oligonucleotides for modulating htra1 expression |
| WO2019121838A1 (en) * | 2017-12-21 | 2019-06-27 | F. Hoffmann-La Roche Ag | Companion diagnostic for htra1 rna antagonists |
| WO2021252799A2 (en) * | 2020-06-11 | 2021-12-16 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing msh3 expression |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6582908B2 (en) * | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
| FR2692265B1 (fr) | 1992-05-25 | 1996-11-08 | Centre Nat Rech Scient | Composes biologiquement actifs de type phosphotriesters. |
| FR2705099B1 (fr) | 1993-05-12 | 1995-08-04 | Centre Nat Rech Scient | Oligonucléotides phosphorothioates triesters et procédé de préparation. |
| US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US6238921B1 (en) * | 1998-03-26 | 2001-05-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of human mdm2 expression |
| US20030228597A1 (en) * | 1998-04-13 | 2003-12-11 | Cowsert Lex M. | Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation |
| US20040226056A1 (en) * | 1998-12-22 | 2004-11-11 | Myriad Genetics, Incorporated | Compositions and methods for treating neurological disorders and diseases |
| US5998148A (en) * | 1999-04-08 | 1999-12-07 | Isis Pharmaceuticals Inc. | Antisense modulation of microtubule-associated protein 4 expression |
| US20020055479A1 (en) * | 2000-01-18 | 2002-05-09 | Cowsert Lex M. | Antisense modulation of PTP1B expression |
| US6423543B1 (en) * | 2000-12-20 | 2002-07-23 | Isis Pharmaceuticals, Inc. | Antisense modulation of hepsin expression |
| US6869768B2 (en) * | 2001-09-07 | 2005-03-22 | City Of Hope | Association between the acid phosphatase (ACP1) gene and Alzheimer's disease |
| WO2003038045A2 (en) * | 2001-10-29 | 2003-05-08 | City Of Hope | Acid phosphatase (acp1) gene as a susceptibility locus for hyperlipidemia |
| US7662770B2 (en) * | 2002-05-23 | 2010-02-16 | Purdue Research Foundation | Low molecular weight protein tyrosine phosphatase (LMW-PTP) as a diagnostic and therapeutic target |
| US20050164254A1 (en) * | 2002-06-14 | 2005-07-28 | Bennett C. F. | Compositions and their uses directed to metabolic proteins |
| EP1572713A4 (en) * | 2002-08-14 | 2006-05-24 | Pharmacia Corp | ANTISENSE MODULATION OF ACYL-COA SYNTHETASE 1 EXPRESSION |
| AU2003295600A1 (en) * | 2002-11-14 | 2004-06-15 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
| US20050147593A1 (en) * | 2003-05-22 | 2005-07-07 | Medimmune, Inc. | EphA2, EphA4 and LMW-PTP and methods of treatment of hyperproliferative cell disorders |
| JP4888065B2 (ja) * | 2005-12-08 | 2012-02-29 | オムロン株式会社 | レーザスキャン装置 |
-
2006
- 2006-05-24 EP EP11194974A patent/EP2462937A1/en not_active Ceased
- 2006-05-24 CA CA002609180A patent/CA2609180A1/en not_active Abandoned
- 2006-05-24 JP JP2008513714A patent/JP2008541729A/ja active Pending
- 2006-05-24 EP EP06771192A patent/EP1888083B1/en not_active Not-in-force
- 2006-05-24 AU AU2006249925A patent/AU2006249925A1/en not_active Abandoned
- 2006-05-24 US US11/915,124 patent/US20090221671A1/en not_active Abandoned
- 2006-05-24 WO PCT/US2006/020272 patent/WO2006127913A2/en not_active Ceased
- 2006-05-24 AT AT06771192T patent/ATE538798T1/de active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2609180A1 (en) | 2006-11-30 |
| AU2006249925A1 (en) | 2006-11-30 |
| EP1888083A4 (en) | 2009-10-21 |
| EP1888083B1 (en) | 2011-12-28 |
| EP2462937A1 (en) | 2012-06-13 |
| WO2006127913A3 (en) | 2007-04-12 |
| US20090221671A1 (en) | 2009-09-03 |
| JP2008541729A (ja) | 2008-11-27 |
| WO2006127913A2 (en) | 2006-11-30 |
| EP1888083A2 (en) | 2008-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201000914A1 (ru) | Новые терапевтические подходы в лечении смт и связанных с ней расстройств | |
| WO2007131232A3 (en) | Compositions and their uses directed to ptpr alpha | |
| CY1115180T1 (el) | Επιλογες θεραπειας για τη νοσο του fabry | |
| ATE456369T1 (de) | Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen | |
| WO2007055950A3 (en) | Polycation-polyanion complexes, compositions and methods of use thereof | |
| EA200900741A1 (ru) | Способы лечения гиперхолестеринемии | |
| EA200601746A1 (ru) | Применение ротиготина для лечения и предупреждения синдрома "паркинсонизм-плюс" | |
| ATE534378T1 (de) | Titrierung von tapentadol | |
| EA200800661A1 (ru) | Полимерные конъюгаты k-252а и его производных | |
| CR9427A (es) | Combinacion terapeutica en casos de hiperplasia prostatica benigna | |
| UA111360C2 (uk) | ПОХІДНІ 4-АМІНО-7,8-ДИГІДРОПІРИМІДО[4,5-f][1,4]ОКСАЗЕПІН-5-ОНУ ЯК ІНГІБІТОРИ ДІАЦИЛГЛІЦЕРОЛАЦИЛТРАНСФЕРАЗИ | |
| SE0401345D0 (sv) | Therapeutic compounds: Pyridine as scaffold | |
| EA201000855A1 (ru) | Способ и средства для достижения бронхиальной релаксации | |
| MX2009003516A (es) | Formas de dosificacion solidas farmaceuticas que comprenden compuestos microincluidos en polimeros ionicos insolubles en agua. | |
| WO2008063768A3 (en) | Compositions and methods for treating metabolic diseases | |
| ATE538798T1 (de) | Zusammensetzungen und ihre verwendungen gegen niedermolekulare ptpase | |
| EA200601869A1 (ru) | Карбоновые кислоты | |
| WO2007083119A3 (en) | Methods | |
| DE602006001699D1 (de) | Stabile pharmazeutische Zusammensetzung mit Linezolid Form IV | |
| WO2007137301A3 (en) | Modulation of chrebp expression | |
| EA200900259A1 (ru) | Лечение ревматоидного заболевания глюкокортикоидами с отсроченным высвобождением | |
| WO2008011473A3 (en) | Compositions and their uses directed to hbxip | |
| WO2006091841A3 (en) | Compositions and their uses directed to il-4r alpha | |
| WO2007109174A3 (en) | Compositions and methods for modulation of mcl-1 expression | |
| WO2006127976A3 (en) | Compositions and their uses directed to ptpru |